CyDex

CyDex is a leader in drug formulation technologies aimed at improving the solubility of medications in the bloodstream by using compounds know as anionically charged sulfobutylether-cyclodextrins. CyDex, Inc. was established to license and commercialize modified cyclodextrins for use in drug development and formulation. The series of anionically charged sulfobutyl ether ß-cyclodextrins (SBE-CDs) were originally synthesized and patented by scientists from the University of Kansas Higuchi Biosciences Center for Drug Delivery Research. CyDex has an exclusive license to the SBE cyclodextrins. Two SBE-CD products are available commercially, CAPTISOL® and Advasep®. CAPTISOL is a drug formulation technology and Advasep is used in chiral and achiral separations by CE and HPLC and in tissue imaging

Activity:

- Manufacturing

Product / Technology type(s) covered:

- Technology

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: